Teva Pharmaceutical Industries Ltd. has filed patent infringement complaints against number of pharmaceutical companies which manufacture generic Zoloft (generically known as sertraline hydrochloride). Teva filed the complaints in the US District Courts of New Jersey, Delaware, Southern District New York, and Maryland for infringement of its U.S. Patent Nos. 6,600,073 (the ‘073 patent), 6,500,987 (the ‘987 patent), 6,495,721 (the ‘721 patent) and 6,897,340 (the ‘340 patent). Back in August, Teva launched generic Zoloft with 180-days marketing exclusivity after Pfizer lost its patent protection for sertraline hydrochloride in June last year. The exclusivity is due to end on February 6, 2007. In its complaint, Teva did not mentioned names of the companies or the number of firms it is suing.
Official Press Release.
No comments:
Post a Comment